Kindred Biosciences, Inc. (KIN) Financial Statements (2024 and earlier)

Company Profile

Business Address 1555 BAYSHORE HIGHWAY, SUITE 200
BURLINGAME, CA 94010
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2021
MRQ
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including: 59,90073,50073,90082,51956,75573,043
Cash and cash equivalents 11,62015,98656,30234,8136,68719,992
Short-term investments 46,75855,72317,63046,20750,06853,051
Other undisclosed cash, cash equivalents, and short-term investments 1,5221,791(32)1,499  
Receivables 624923903   
Inventory, net of allowances, customer advances and progress billings 2074,2183,570   
Inventory 2074,2183,570   
Other undisclosed current assets 1,8937041,696(702)1,282712
Total current assets: 62,62479,34580,06981,81758,03773,755
Noncurrent Assets
Operating lease, right-of-use asset 3,4283,001
Property, plant and equipment 28,20429,77726,3437,4572,4411,244
Long-term investments and receivables 1,5001,837 1,4991,0524,590
Long-term investments 1,5001,837 1,4991,0524,590
Other noncurrent assets 586470494630
Total noncurrent assets: 33,19034,67926,4139,0053,5395,864
TOTAL ASSETS: 95,814114,024106,48290,82261,57679,619
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 4,9609,58015,1816,0273,8673,208
Employee-related liabilities 2,0704,1933,4362,6881,8071,922
Accounts payable 1451,2563,5761,439410717
Accrued liabilities 2,7454,1318,1691,9001,650569
Debt 1,111644    
Other undisclosed current liabilities 825     
Total current liabilities: 6,89610,22415,1816,0273,8673,208
Noncurrent Liabilities
Long-term debt and lease obligation 21,43621,879    
Long-term debt, excluding current maturities 18,50219,265    
Liabilities, other than long-term debt   941152940
Accounts payable and accrued liabilities   941152940
Operating lease, liability 2,9342,614
Other undisclosed noncurrent liabilities (2,934)     
Total noncurrent liabilities: 21,43621,879941152940
Total liabilities: 28,33232,10315,2756,1423,8963,248
Equity
Equity, attributable to parent 67,48281,92191,20784,68057,68076,371
Common stock 443322
Additional paid in capital 312,321304,963252,885196,688138,810135,021
Accumulated other comprehensive income (loss) 1213(11)(31)(31)(50)
Accumulated deficit (244,855)(223,059)(161,670)(111,980)(81,101)(58,602)
Total equity: 67,48281,92191,20784,68057,68076,371
TOTAL LIABILITIES AND EQUITY: 95,814114,024106,48290,82261,57679,619

Income Statement (P&L) ($ in thousands)

6/30/2021
TTM
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues 42,1644,2561,966   
Cost of revenue
(Cost of Goods and Services Sold)
 (4,626)(587)(324)   
Gross profit: 37,5383,6691,642   
Operating expenses (57,506)(66,448)(53,222)(31,653)(22,824)(27,262)
Other undisclosed operating income  212324   
Operating loss: (19,968)(62,567)(51,256)(31,653)(22,824)(27,262)
Nonoperating income (expense) (1,828)1,1781,566774325132
Investment income, nonoperating 281,1781,566774325132
Loss from continuing operations: (21,796)(61,389)(49,690)(30,879)(22,499)(27,130)
Loss before gain (loss) on sale of properties:(21,796)(61,389)(49,690)(30,879)(22,499)(27,130)
Net loss available to common stockholders, diluted: (21,796)(61,389)(49,690)(30,879)(22,499)(27,130)

Comprehensive Income ($ in thousands)

6/30/2021
TTM
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss: (21,796)(61,389)(49,690)(30,879)(22,499)(27,130)
Comprehensive loss: (21,796)(61,389)(49,690)(30,879)(22,499)(27,130)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent (1)2420 19(23)
Comprehensive loss, net of tax, attributable to parent: (21,797)(61,365)(49,670)(30,879)(22,480)(27,153)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: